NCT02518750: Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma |
|
|
| Terminated | 2 | 3 | US | Dexamethasone, Decadron®, Panobinostat, LBH589, Liposomal vincristine, Vincristine sulfate liposome injection, VSLI, Marqibo®, Mitoxantrone, Novantrone®, Peg-asparaginase, Peg-L-asparaginase, Pegaspargase, Oncaspar®, Bortezomib, Velcade, MLN341, LDP-341, Intrathecal Triples, ITMHA, Methotrexate/Hydrocortisone/Cytarabine, High-dose methotrexate, HDMTX, 6-Mercaptopurine, 6-MP, Purinethol®, High-dose cytarabine, Ara-C, Cytosar-U®, Nelarabine, Arranon®, Compound 506U78, Cyclophosphamide, Cytoxan®, Etoposide, VP-16, Vepesid®, Clofarabine, Clolar™, Clofarex | St. Jude Children's Research Hospital, Novartis Pharmaceuticals, Spectrum Pharmaceuticals, Inc | Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell | 03/18 | 03/18 | | |
